Merrimack Pharmaceuticals Inc. To Present Phase 1 Data On MM-302 In Patients With Advanced HER2-Positive Breast Cancer

Published: Dec 06, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Dec. 6, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Phase 1 data evaluating safety of the novel agent MM-302 in patients with advanced HER2-positive breast cancer will be presented at the 2013 San Antonio Breast Cancer Symposium (SABCS), December 10-14, 2013 in San Antonio, Texas.

Help employers find you! Check out all the jobs and post your resume.

Back to news